| Bioactivity | CP 316819 is a potent glycogen phosphorylase (GPase) inhibitor with antihyperglycemic effect (IC50 values are 17 and 34 nM against human skeletal muscle glycogen phosphorylase (huSMGPa) and liver glycogen phosphorylase (huLGPa) respectively).CP 316819 causes glycogen accumulation under normoglycemic conditions but permits glycogen utilization when glucose concentrations are low.CP-316819 prevents neuronal cell death and maintains brain electrical currents[1][2]. | ||||||||||||
| Name | CP-316819 | ||||||||||||
| CAS | 186392-43-8 | ||||||||||||
| Formula | C21H22ClN3O4 | ||||||||||||
| Molar Mass | 415.87 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Baker DJ, Timmons JA, Greenhaff PL. Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle. Diabetes. 2005 Aug;54(8):2453-9. [2]. Suh SW, Bergher JP, Anderson CM, Treadway JL, Fosgerau K, Swanson RA. Astrocyte glycogen sustains neuronal activity during hypoglycemia: studies with the glycogen phosphorylase inhibitor CP-316,819 ([R-R*,S*]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3 |
CP-316819
CAS: 186392-43-8 F: C21H22ClN3O4 W: 415.87
CP 316819 is a potent glycogen phosphorylase (GPase) inhibitor with antihyperglycemic effect (IC50 values are 17 and 34
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.